GlassScriptPhysician profile
Lester I Marion
NPI 1336151711
$704.22
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2021: $20.99.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $147.36 | 2019 | |
| Abbvie INC. | $141.96 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $141.31 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.18 | 2019 | |
| Vivus LLC | $38.50 | 2019 | |
| Daiichi Sankyo INC. | $31.21 | 2019 | |
| Braintree Laboratories, INC. | $26.79 | 2019 | |
| Allergan, INC. | $26.61 | 2019 | |
| Merck Sharp & Dohme LLC | $17.93 | 2019 | |
| Boston Scientific Corporation | $11.37 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lester Marion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.